ArticleJournal of molecular histology2025
The metformin administration on pancreatic tissue damage in metastatic rat prostate cancer and STZ induced diabetes model.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is the major cause of mortality in most nations, and a severe health problem worldwide. According to epidemiological studies, diabetes shows an increased risk for a variety of cancers. Metformin is a semisynthetic biguanide produced from the French lilac plant. The effects of metformin on pancreatic tissue damage in cancer and diabetic rat models were evaluated histologically and biochemically in the present study. The diabetes model was induced in Copenhagen rats using a single dose of streptozotocin, while prostate cancer was induced through subcutaneous inoculation of MAT-LyLu cells into the animals. Metformin was administered by gavage daily after inoculation of the Mat-Lylu cells. Histological evaluation showed moderate to severe damage to the pancreas following diabetes and cancer process. Administration of metformin reversed these effects showing a beneficial effect of metformin. Metformin treatment can be considered an adjuvant candidate for pancreas tissue in diabetes, prostate cancer and cancer therapy related damage. Metformin alleviates diabetes and cancer induced pancreatic cytotoxicity by regulating oxidative stress and antioxidant capacity. More research will be needed to explore the metformin effect.
Indexed as
Identifiers
40542925What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.